Control criteria for glycosylated hemoglobin in diabetes mellitus

Diabetes glycosylated hemoglobin control standard is less than 7%.

In general, most diabetes patients glycosylated hemoglobin control target should be less than 7%. However, specific control standards need to be individualized according to the patient's age, course of disease, health status, with or without complications and other factors. For young patients with short duration, long life expectancy and no obvious complications such as cardiovascular disease, glycosylated hemoglobin can be controlled at a stricter level, such as less than 6,5% or even close to the normal range, which helps to reduce the risk of diabetic microvascular complications, such as retinopathy, kidney disease, etc. Strict control of glycosylated hemoglobin can better maintain long-term stability of blood sugar and delay the progression of the disease

. For patients with a history of severe hypoglycemia, limited life expectancy, significant cardiovascular disease or other serious complications, the target of glycosylated hemoglobin control may be appropriately relaxed, such as less than 8% or even higher. This is because too strict glycemic control may increase the risk of hypoglycemia, and severe hypoglycemia may bring more serious adverse consequences to such patients, such as induced arrhythmia, cerebral ischemia, etc., or even life-threatening. At the same time, appropriate relaxation of control standards can also improve the quality of life of patients to a certain extent, reducing the psychological burden and treatment pressure caused by strict control of blood sugar.

In addition, for gestational diabetes patients, in order to reduce the adverse effects on the fetus, glycosylated hemoglobin should be controlled within a stricter range, generally less than 6%. This needs to be achieved by closely monitoring blood sugar and adjusting treatment options reasonably to ensure stable blood sugar during pregnancy.